Kerwin F Shannon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1695350/publications.pdf

Version: 2024-02-01

86 papers	4,300 citations	126708 33 h-index	110170 64 g-index
88 all docs	88 docs citations	88 times ranked	4294 citing authors

#	Article	IF	Citations
1	Experience with 998 cutaneous melanomas of the head and neck over 30 years. American Journal of Surgery, 1991, 162, 310-314.	0.9	471
2	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 948-960.	5.1	346
3	Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncology, The, 2012, 13, 589-597.	5.1	253
4	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	5.8	205
5	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature Medicine, 2021, 27, 256-263.	15.2	190
6	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1049-1060.	5.1	173
7	Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes. Cancer, 2006, 106, 1078-1083.	2.0	147
8	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Annals of Surgical Oncology, 2015, 22, 475-481.	0.7	131
9	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€“C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	5.1	126
10	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	15.2	121
11	Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy. Annals of Surgical Oncology, 2005, 12, 429-439.	0.7	109
12	Correlation Between Preoperative Lymphoscintigraphy and Metastatic Nodal Disease Sites in 362 Patients With Cutaneous Melanomas of the Head and Neck. Annals of Surgery, 2004, 239, 544-552.	2.1	106
13	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery, 2012, 255, 128-133.	2.1	103
14	Lymph node ratio as an independent prognostic factor in oral squamous cell carcinoma. Head and Neck, 2011, 33, 1245-1251.	0.9	101
15	Alterations in miRNA processing and expression in pleomorphic adenomas of the salivary gland. International Journal of Cancer, 2009, 124, 2855-2863.	2.3	87
16	Keystone Flap Reconstruction of Primary Melanoma Excision Defects of the Legâ€”The End of the Skin Graft?. Annals of Surgical Oncology, 2008, 15, 2867-2873.	0.7	85
17	Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary. Head and Neck, 2010, 32, 1288-1294.	0.9	72
18	Prospective study of sentinel node biopsy for highâ€risk cutaneous squamous cell carcinoma of the head and neck. Head and Neck, 2016, 38, E884-9.	0.9	69

#	Article	IF	Citations
19	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	7.7	64
20	Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. Annals of Surgery, 2009, 249, 473-480.	2.1	61
21	Close margin alone does not warrant postoperative adjuvant radiotherapy in oral squamous cell carcinoma. Cancer, 2013, 119, 2427-2437.	2.0	59
22	Outcomes of primary surgical treatment of T1 and T2 carcinomas of the oropharynx. Laryngoscope, 2009, 119, 307-311.	1.1	58
23	The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. Annals of Surgery, 2013, 258, 152-157.	2.1	56
24	False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Research, 2009, 19, 94-99.	0.6	53
25	Perineural invasion in oral squamous cell carcinoma: Quantitative subcategorisation of perineural invasion and prognostication. Journal of Surgical Oncology, 2015, 111, 352-358.	0.8	52
26	Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australasian Journal of Dermatology, 2009, 50, 266-271.	0.4	48
27	Outcome of treatment for advanced cervical metastatic squamous cell carcinoma. Head and Neck, 2005, 27, 87-94.	0.9	47
28	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Caseâ€“Control Study. Annals of Surgical Oncology, 2016, 23, 1082-1089.	0.7	43
29	Surgeonsâ€™ Opinions on Lymphadenectomy in Melanoma Patients with Positive Sentinel Nodes: A Worldwide Web-Based Survey. Annals of Surgical Oncology, 2012, 19, 4322-4329.	0.7	42
30	Margins of excision and prognostic factors for cutaneous eyelid melanomas. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2013, 66, 1066-1073.	0.5	42
31	Orbital exenterations: an 18-year experience from a single head and neck unit. ANZ Journal of Surgery, 2011, 81, 326-330.	0.3	41
32	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. Journal of Clinical Oncology, 2017, 35, 1721-1729.	0.8	40
33	Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Modern Pathology, 2018, 31, 275-287.	2.9	37
34	Adjuvant Postoperative Radiotherapy to the Cervical Lymph Nodes in Cutaneous Melanoma: Is There Any Benefit for High-Risk Patients?. Annals of Surgical Oncology, 2008, 15, 3022-3027.	0.7	36
35	Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma. Annals of Surgery, 2014, 260, 149-157.	2.1	36
36	Mutational Patterns in Metastatic Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2019, 139, 1449-1458.e1.	0.3	36

#	Article	IF	Citations
37	Primary Melanoma Location on the Scalp is an Important Risk Factor for Brain Metastasis: A Study of 1,687 Patients with Cutaneous Head and Neck Melanomas. Annals of Surgical Oncology, 2014, 21, 3985-3991.	0.7	35
38	Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. Annals of Surgical Oncology, 2014, 21, 3108-3116.	0.7	33
39	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Modern Pathology, 2017, 30, 1538-1550.	2.9	33
40	Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head and Neck, 2009, 31, 244-250.	0.9	32
41	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1â€“2Âmm in Thickness): Analysis of 2131 Patients Treated at a Single Center. Annals of Surgical Oncology, 2016, 23, 1071-1081.	0.7	31
42	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 1782-1789.	0.7	30
43	Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ Journal of Surgery, 2009, 79, 378-382.	0.3	23
44	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	0.8	23
45	Î³Î´ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. Cancer Immunology Research, 2021, 9, 612-623.	1.6	22
46	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	0.7	21
47	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surgery, 2022, 157, 335.	2.2	20
48	Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. European Journal of Surgical Oncology, 2015, 41, 830-836.	0.5	19
49	Contralateral neck failure in lateralized oral squamous cell carcinoma. ANZ Journal of Surgery, 2016, 86, 188-192.	0.3	17
50	Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology, 2021, 34, 1999-2008.	2.9	16
51	The Unpredictability of Lymphatic Drainage from the Ear in Melanoma Patients, and Its Implications for Management. Annals of Surgical Oncology, 2013, 20, 1707-1713.	0.7	14
52	Small Cell Neuroendocrine Carcinoma Masquerading as Cellulitis and Causing Blindness via Bilateral Orbital Involvement. Orbit, 2013, 32, 197-199.	0.5	14
53	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer, 2020, 126, 4717-4725.	2.0	14
54	Free flap reconstruction for melanoma of the head and neck: indications and outcomes. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2010, 63, 205-212.	0.5	13

#	Article	IF	Citations
55	Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). Journal of Clinical Oncology, 2009, 27, LBA9084-LBA9084.	0.8	11
56	Traumatic vertebro-jugular arteriovenous fistula successfully treated by percutaneous embolization. ANZ Journal of Surgery, 2001, 71, 688-692.	0.3	10
57	Reticular and microcystic schwannoma of the parotid gland. Pathology, 2013, 45, 96-98.	0.3	10
58	Assessment of second tier lymph nodes in melanoma and implications for extent of elective neck dissection in metastatic cutaneous malignancy of the parotid. Head and Neck, 2013, 35, 205-208.	0.9	9
59	Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications. Annals of Surgical Oncology, 2017, 24, 2071-2079.	0.7	9
60	Multiplex melanoma families are enriched for polygenic risk. Human Molecular Genetics, 2020, 29, 2976-2985.	1.4	9
61	Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). Journal of Clinical Oncology, 2009, 27, LBA9084-LBA9084.	0.8	9
62	Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01).. Journal of Clinical Oncology, 2013, 31, 9001-9001.	0.8	8
63	Papillary Endothelial Hyperplasia of the Orbit. Acta Cytologica, 2007, 51, 207-210.	0.7	7
64	Treatment of advanced cancer of the larynx and hypopharynx with chemoradiation. ANZ Journal of Surgery, 2004, 74, 554-558.	0.3	6
65	Evaluation of Incomplete Sentinel Node Biopsy Procedures and Sentinel Node Positivity Rates as Surgical Quality-Assurance Parameters in Melanoma Patients. Annals of Surgical Oncology, 2012, 19, 3919-3925.	0.7	6
66	Surgical management of the neck in patients with metastatic melanoma in parotid lymph nodes. Journal of Surgical Oncology, 2019, 120, 1462-1469.	0.8	6
67	Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?. Journal of Clinical Pathology, 2020, 73, 17-22.	1.0	6
68	The significance of regional metastasis location in head and neck cutaneous squamous cell carcinoma. Head and Neck, 2021, 43, 2705-2711.	0.9	6
69	Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 2020, 46, 2131-2139.	0.5	5
70	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. European Journal of Surgical Oncology, 2021, 47, 1145-1151.	0.5	5
71	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	1.3	4
72	Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. Melanoma Research, 2008, 18, 161-162.	0.6	3

#	Article	IF	Citations
73	Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. Annals of Surgical Oncology, 2019, 26, 4663-4672.	0.7	3
74	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.3	3
75	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 2022, 167, 133-141.	1.3	3
76	Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 6991-6999.	0.7	2
77	HN08P AUDIT OF 115 CONSECUTIVE PARATHYROIDECTOMIES IN PATIENTS WITH RENAL HYPERPARATHYROIDISM. ANZ Journal of Surgery, 2007, 77, A38-A38.	0.3	1
78	Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma. ANZ Journal of Surgery, 2021, , .	0.3	1
79	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	1.3	1
80	Outcomes after definitive treatment for head and neck angiosarcoma. ANZ Journal of Surgery, 2022, , .	0.3	1
81	How important is multidisciplinary treatment of melanoma metastases?. Expert Review of Dermatology, 2013, 8, 339-341.	0.3	0
82	Oral Mucosal Melanoma. , 2013, , 1915-1918.		0
83	Laryngeal Mucosal Melanoma. , 2013, , 1426-1428.		0
84	Sinonasal Mucosal Melanoma. , 2013, , 2432-2438.		0
85	Effect of the <scp>SunSafe</scp> Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. Clinical and Experimental Dermatology, 2022, , .	0.6	0
86	Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Research, 2022, Publish Ahead of Print, .	0.6	0